Updates and advances in pyruvate kinase deficiency.

Area of Science:

• Genetics and Hematology
• Red Blood Cell Metabolism
• Congenital Hemolytic Anemias

Background:

• Pyruvate kinase (PK) deficiency results from PKLR gene mutations, leading to chronic hemolytic anemia due to impaired red blood cell energy.
• This condition causes significant morbidity and reduced quality of life, with limited historical treatment options.
• Supportive care, including transfusions and splenectomy, has been the mainstay of management.

Purpose of the Study:

• To review current and emerging treatment strategies for pyruvate kinase deficiency.
• To highlight the significance of disease-modifying therapies in managing this rare anemia.
• To discuss the ongoing evaluation of novel treatments and their long-term effects.

Main Methods:

• Literature review of pyruvate kinase deficiency and its management.
• Analysis of current therapeutic approaches, including supportive care and disease-modifying agents.
• Discussion of ongoing clinical trials for gene therapy and PK activators.

Main Results:

• Mitapivat, an oral allosteric PK activator, is a newly approved disease-modifying treatment for adults with PK deficiency.
• Gene therapy is under investigation in clinical trials as a potential curative approach.
• Research is expanding to evaluate PK activators in other congenital hemolytic anemias.

Conclusions:

• Disease-modifying therapies represent a significant advancement in managing pyruvate kinase deficiency.
• Mitapivat offers a new treatment option, shifting from solely supportive care.
• Continued evaluation is necessary to understand the long-term impact of these novel treatments on patient outcomes.